THE ADJUVANT TREATMENT OF STAGE 3 COLON CANCER (ACC): AN INDIRECT COST-MINIMISATION AND POPULATION NET HEALTH BENEFIT ANALYSIS OF CAPECITABINE plus OXALIPLATIN (XELOX) VS. IV 5-FU + FA + OXALIPLATIN (FOLFOX) | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

7192929

Reference Type

Journal Article

Title

THE ADJUVANT TREATMENT OF STAGE 3 COLON CANCER (ACC): AN INDIRECT COST-MINIMISATION AND POPULATION NET HEALTH BENEFIT ANALYSIS OF CAPECITABINE plus OXALIPLATIN (XELOX) VS. IV 5-FU + FA + OXALIPLATIN (FOLFOX)

Author(s)

Garside, J; Mcnamara, S; Millar, D; ,

Year

2011

Publisher

ELSEVIER SCIENCE INC

Location

NEW YORK

Page Numbers

A453-A453

Web of Science Id

WOS:000299107101277

Conference Location